Andrew Yee, MD

home / authors / andrew-yee-md

Articles

Andrew Yee, MD

Dr. Yee on Treating Patients with Relapsed Disease in Multiple Myeloma

Andrew Yee, MD
June 19th 2022

Andrew Yee, MD, discusses treating patients with relapsed disease in multiple myeloma.

Read More

Dr. Yee on the Utility of Isatuximab in Combination Therapy for Relapsed/Refractory Myeloma

Dr. Yee on the Utility of Isatuximab in Combination Therapy for Relapsed/Refractory Myeloma

Andrew Yee, MD
July 6th 2020

Andrew Yee, MD, discusses the utility of isatuximab-irfc in relapsed/refractory multiple myeloma.

Read More

Dr. Yee on the Results of the CANDOR Trial in Relapsed/Refractory Myeloma

Dr. Yee on the Results of the CANDOR Trial in Relapsed/Refractory Myeloma

Andrew Yee, MD
May 20th 2020

Andrew Yee, MD, discusses the phase 3 CANDOR trial in relapsed/refractory multiple myeloma.

Read More

Dr. Yee on Trials Evaluating Treatment in Lenalidomide-Refractory Multiple Myeloma

Dr. Yee on Trials Evaluating Treatment in Lenalidomide-Refractory Multiple Myeloma

Andrew Yee, MD
May 18th 2020

Andrew Yee, MD, discusses trials evaluating treatment for patients with lenalidomide-refractory multiple myeloma.

Read More

Dr. Yee on the Role of Carfilzomib in Relapsed/Refractory Multiple Myeloma

Dr. Yee on the Role of Carfilzomib in Relapsed/Refractory Multiple Myeloma

Andrew Yee, MD
May 4th 2020

Andrew Yee, MD, discusses the role of carfilzomib in relapsed/refractory multiple myeloma.

Read More

Dr. Yee on Treatment Considerations in Relapsed/Refractory Multiple Myeloma

Dr. Yee on Treatment Considerations in Relapsed/Refractory Multiple Myeloma

Andrew Yee, MD
April 22nd 2020

Andrew Yee, MD, discusses treatment considerations in relapsed/refractory multiple myeloma.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need